Hillhurst Biopharmaceuticals, Inc.

MONTROSE, CA · Biotech · Private

HBI-002, an oral low-dose carbon monoxide drug product for sickle cell disease

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: MONTROSE, CA
Latest Form D: $1.8M, Sep 2023
Total capital: $15.4M

Federal grants: $13.6M; 28 awards · 2015–2025; Rank in peer group#27 of 514
Private capital raised: $1.8M; 1 Form D · last Sep 2023; 37 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 4 pending

Capital timeline

Latest events

Sep 2025Federal grantHealth and Human S · Phase II · HBI-002 to Treat Diabetic Retinopathy$961K
Jul 2025Federal grantHealth and Human S · Phase II · HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$1.0M
Sep 2024Federal grantHealth and Human S · Phase II · HBI-002 to Treat Diabetic Retinopathy$950K
Apr 2024Federal grantHealth and Human S · Phase I · HBI-002 for Cystic Fibrosis$300K
Apr 2024Federal grantHealth and Human S · Phase II · HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$1.0M
Sep 2023Private capital raisedForm D · SEC · 1st filing$1.8M
Jul 2023Federal grantHealth and Human S · Phase I · Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$300K

Show 22 earlier federal awards

Mar 2023Federal grantHealth and Human S · Phase II · HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$1.0M
Aug 2022Federal grantHealth and Human S · Phase I · HBI-002 to Treat Parkinson’s Disease$181K
Aug 2022Federal grantHealth and Human S · Phase I · Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$300K
Sep 2021Federal grantHealth and Human S · Phase I · HBI-002 to Treat Parkinson’s Disease$453K
Aug 2021Federal grantHealth and Human S · Phase I · HBI-002 to Treat Diabetic Retinopathy$300K
Aug 2021Federal grantHealth and Human S · Phase I · HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$17K
Aug 2021Federal grantHealth and Human S · Phase I · HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$77K
Apr 2021Federal grantHealth and Human S · Phase I · HBI-002 to Treat Ulcerative Colitis$75K
Apr 2021Federal grantHealth and Human S · Phase I · Laboratory training and experience for an undergraduate$6K
Aug 2020Federal grantHealth and Human S · Phase I · HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$222K
May 2020Federal grantHealth and Human S · Phase I · HBI-002 to Treat Ulcerative Colitis$219K
Jul 2019Federal grantHealth and Human S · Phase II · HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$702K
Mar 2019Federal grantHealth and Human S · Phase I · HBI-002 to Treat Traumatic Injury$56K
Sep 2018Federal grantHealth and Human S · Phase II · HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$1.3M
Apr 2018Federal grantHealth and Human S · Phase I · HBI-002 to Treat Traumatic Injury$225K
Jul 2017Federal grantHealth and Human S · Phase II · HBI-002 to Treat Delayed Graft Function in Kidney Transplant$635K
Mar 2017Federal grantHealth and Human S · Phase I · Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$42K
Aug 2016Federal grantHealth and Human S · Phase I · Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke$224K
Aug 2016Federal grantHealth and Human S · Phase II · HBI to Treat Delayed Graft Function in Kidney Transplant$1.5M
Aug 2016Federal grantHealth and Human S · Phase II · HBI-002 to Treat Delayed Graft Function in Kidney Transplant$863K
Apr 2016Federal grantHealth and Human S · Phase I · Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$258K
Sep 2015Federal grantHealth and Human S · Phase I · Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke$476K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

97months

from Hillhurst Biopharmaceuticals, Inc.’s first federal award to its first private round.

First federal award · Sep 2015: Health and Human S · $476K
First Form D · Sep 2023: $1.8M · 1st Form D
Awards before first raise: 23 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#27 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Edward GompertsResearcherExecutive Officer, DirectorLinked by $13.3M in grants as PI
Andrew GompertsExecutive Officer, DirectorNamed in SEC Form D filings
Jeff FriedmanDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 4

Sep 7, 2023PendingEnteral Carbon Monoxide For The Prevention And Treatment Of Ocular DiseasesUSPTOApplication 18179069
PendingSolution Of Nitrous Oxide For The Treatment Of DiseaseUSPTOApplication PCTUS2025012180
PendingSolution Of Nitrous Oxide For The Treatment Of DiseaseUSPTOApplication 63623095

Show all 4 patent records

Enteral Carbon Monoxide For The Prevention And Treatment Of Ocular DiseasesSep 7, 2023 · Application 18179069Pending
Solution Of Nitrous Oxide For The Treatment Of DiseaseApplication PCTUS2025012180Pending
Solution Of Nitrous Oxide For The Treatment Of DiseaseApplication 63623095Pending
Enteral Carbon Monoxide For The Prevention And Treatment Of Ocular DiseasesApplication 63316868Pending

FGH BIOTECH, INC.Similar federal contract value in Biotech · null in contracts
RegulonixSimilar federal contract value in Biotech · null in contracts
4E THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Agilvax, Inc.Similar federal contract value in Biotech · null in contracts
RESOLUTE SCIENCE, INC.Similar federal contract value in Biotech · null in contracts
ZYWIE LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.